Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized multiple-dose study of recifercept in children with achondroplasia
2020-001189-13Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Sep 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of recifercept in achondroplasia (ACH) (2 arms), sponsored by Pfizer. Primary endpoint: Safety and tolerability. Started Sep 2020; status: terminated.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2020-001189-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001189-13.